Lyell Immunopharma (LYEL) Shares Outstanding (2020 - 2026)

Lyell Immunopharma (LYEL) has 6 years of Shares Outstanding (Entity) data on file, last reported at $23.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Entity) rose 58.01% year-over-year to $23.3 million; the trailing twelve-month figure through Mar 2026 stood at $23.3 million (up 58.01% YoY), and the FY2025 full-year result was $17.1 million, up 15.93% from the prior year.
• Shares Outstanding (Entity) improved to $23.3 million in Q1 2026, from $17.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $23.3 million in Q1 2026 to a low of $12.3 million in Q1 2022.
• A 5-year average of $14.3 million and a median of $12.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) soared 578341.01% in 2022 and rose 1.05% in 2023, its largest moves.
• Tracing LYEL's Shares Outstanding (Entity) over 5 years: stood at $12.5 million in 2022, then climbed by 1.76% to $12.7 million in 2023, then advanced by 16.11% to $14.7 million in 2024, then advanced by 15.93% to $17.1 million in 2025, then surged by 36.48% to $23.3 million in 2026.
• Business Quant data shows LYEL's Shares Outstanding (Entity) at $23.3 million in Q1 2026, $17.1 million in Q4 2025, and $19.3 million in Q3 2025.